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Key Points
• Widespread and recurrent alternative splicing differences exist between AML patients with good or poor prognosis
• Missplicing of RNA splicing factors leads to altered splicing of their target transcripts
• Aberrant splicing of protein translation genes triggers the induction of an integrated stress response and concomitant inflammatory response
• Alternative RNA splicing information can be used to improve the accuracy of existing prognostic algorithms in AML Abstract RNA splicing is a fundamental biological process that generates protein diversity from a finite set of genes. Recurrent somatic mutations of splicing factor genes are relatively uncommon in Acute Myeloid Leukemia (AML, < 20%). We examined whether RNA splicing differences exist in AML even in the absence of splicing factor mutations. Analyzing RNA-seq data from two independent cohorts of AML patients, we identified recurrent differential alternative splicing between patients with poor and good prognosis. These alternative splicing events occurred even in patients without any discernible splicing factor mutations. The alternative splicing events recurrently occurred in genes involved in specific molecular functions, primarily related to protein translation. Developing informatics tools to predict the functional impact of alternative splicing on the translated protein, we discovered that ~45% of the splicing events directly affected highly conserved protein domains.
Several splicing factors were themselves misspliced in patients, and the splicing of their target transcripts were also altered. By studying differential gene expression in the same patients, we identified that alternative splicing of protein translation genes in ELN Adv patients resulted in the induction of an integrated stress response and upregulation of inflammation-related genes. Lastly, using machine learning techniques, we identified a set of four genes whose alternative splicing can refine the accuracy of existing risk prognosis schemes and validated it in a completely independent cohort.
Our discoveries therefore identify aberrant alternative splicing as a molecular feature of adverse AML with clinical relevance.
Introduction
Acute Myeloid Leukemia (AML) is a hematological malignancy associated with a poor prognosis and a <30% five-year survival rate 1 . With an incidence rate of 4 per 100,000 adults per year 2 and a five-fold higher rate in people over the age of 65 , AML represents ~40% of all new adult-onset leukaemias in developed societies 3 .
AML is characterized by the clonal proliferation of undifferentiated myeloid precursor cells in the bone marrow and impaired haematopoiesis 4 . AML patients have recurrent somatic driver mutations [5] [6] [7] in addition to characteristic cytogenetic and chromosomal abnormalities. These alterations have prognostic significance and are used to classify AML 5 . However, not all of these mutations are exclusive to AML, with many also being detected in Myelodysplastic Syndrome (MDS) 8, 9 as well as in healthy individuals with age-related clonal haematopoiesis 10, 11 .
The standard of care treatment for AML is intensive induction chemotherapy.
However, despite complete remission (CR) rates of >50%, long term disease-free survival remains poor at <10% and a median overall survival of less than 12 months in patients aged over 60 years 12 . Additionally, because of significant co-morbidities, intensive chemotherapy may not suit older patients 13, 14 . Alternate therapies for these individuals may include lower-intensity treatments, DNA hypomethylating agents (HMA) 15, 16 or targeted therapies. However, response rates and survival benefits still remain poor 17 , highlighting an important need to develop new therapeutic options for the management of AML.
In order to develop more effective drugs for AML, it is necessary to better understand the molecular aberrations present in leukemic cells. Aberrations in RNA splicing, a fundamental and highly conserved process occurring in >95% of multiexon human genes 18 , are increasingly being described in many cancers 19 . Splicing is a co-transcriptional event, orchestrated by cis-acting regulatory elements as well as trans-acting factors of the spliceosomal complex 20 . Pan-cancer studies have begun to reveal that tumors have an average of ~20% more alternative splicing events than in healthy samples 19, 21 . Dysregulation of the expression of splicing factors 22, 23 and upstream signaling pathways 24 as well as genomic mutations in cis-splice sites 25, 26 have all been reported in cancers. Additionally, in hematological malignancies such as MDS and Chronic Myelomonocytic Leukemia, recurrent somatic mutations in members of the E-and A-splicing complexes, such as SF3B1, U2AF1, SRSF2 and ZRSR2 are detected in >50% of patients 8, 9, 27 . The exact mechanisms through which these mutations contribute to the malignancy remain poorly understood. U2AF1 and SF3B1 mutations might alter the 3' splice site in target transcripts [28] [29] [30] , SRSF2 hotspot mutations affect the preferred binding motif on transcripts [31] [32] [33] while ZRSR2 gain-offunction mutations increase intron retention 34 . The different mutations have been proposed to affect unique sets of genes 29, 33 although convergence has been proposed at the level of pathways 35 or through the induction of R-loops 36 .
Somatic mutations in the splicing machinery are less frequent in AML however. Analyses of large cohorts of patients have determined the overall frequency of splicing mutations to be <20% 6, 7 . However, widespread dysregulation of RNA splicing has been observed even in cancers with low frequencies of splicing factor mutations 19, 21, 37 . We therefore examined whether RNA splicing alterations exist in AML even in the absence of somatic splicing factor mutations, and whether it correlates with disease outcome.
Methods

Patient cohorts
Data from two adult AML cohorts were used in the discovery phase of the study: The Cancer Genome Atlas (TCGA)-AML cohort 38 and the Clinseq-AML cohort 39 . Data from the Beat-AML cohort 7 was used to validate significance of the splicing signature. Full details are provided as Supplemental Data.
RNA-seq data analyses
RNA-seq data were analyzed for multiple types of alternative splicing using a custom in-house bioinformatics pipeline incorporating available tools, including
Mixture of Isoforms (MISO) to determine Percent Spliced In (PSI) values in each sample and rMATS for differential splicing analyses. Differential gene expression analyses were performed using DESeq2. A custom in-house pipeline was developed to identify possible changes in well-annotated protein domains due to differentially spliced events. Full details are provided as Supplemental Data.
Transcript motif analyses
Predictions of differential binding of RNA binding proteins were made using rMAPS 40 . Maximum entropy modeling was done with MaxEntScan 41 . Full details are provided as Supplemental Data.
Prognostic model generation
The splicing signature was generated using LASSO Cox Regression with ten fold cross validation implemented in glmnet (R package v 2.0-16) 42 . The splicing risk score for each patient was calculated from the regression coefficients. Performances of prognostic models were assessed by Harrel's C index. Risk contributions and variable importance of all prognostic models were estimated as described previously 43 . Full details are provided as Supplemental Data.
Results
Identification of differential alternative splicing related to outcome in AML patients
To determine whether RNA splicing alterations might be a factor in adverse outcomes in AML, we developed a bioinformatics pipeline to quantify differential alternative splicing in RNA-seq data. We first analyzed AML transcriptomes from
The Cancer Genome Atlas (TCGA) 6 . To detect whether splicing alterations can exist even in the absence of any somatic mutations in splicing factors, we focused our analyses on patients who did not have any splicing factor mutations using the available somatic mutation data 6 . To validate the mutational data, we queried the RNA-seq data to detect the presence of known splicing factor hotspot mutations 27 in transcripts. We confirmed the mutation data in all patients identified to have splicing factor mutations and identified an additional sixteen patients with splicing factor hotspot mutations detectable in the RNA-seq data (fourteen with SRSF2 and one each with SF3B1 and ZRSR2). Our findings of TCGA-AML patients with unannotated splicing mutations is consistent with a recent independent report 44 .
We stratified patients in the TCGA-AML using the widely used European LeukemiaNet (ELN) prognostic scheme 1,4 ( Fig 1A) and restricted the analysis to patients who received intensive induction chemotherapy and for whom full clinical data was available (n=104, Supplementary Table 1 ). Performing differential splicing analyses between ELN Fav and ELN Adv (Fig 1B) , studying the five different types of alternative splicing events (schematized in Fig 1C) , we identified 1288 differentially spliced events (at FDR ≤0.05) in 910 genes ( Fig 1D, Supplementary Table 2 ). A majority of the events involved the differential skipping (or retention) of exons preferentially in one set of patients (n=716, 55.5%, Fig 1D) . Of these, 395 events involved preferential skipping of exons in ELN Adv patients ( Supplementary Fig 1A) ,
with the remaining (n=321) associated with exon skipping in ELN Fav patients. An example of differential exon usage was the skipping of exon 37 of MYO9B in TCGA-ELN Fav patients ( Fig 1E) . Only reads spanning exon 36 -exon 38 were detected in ELN Fav patients (representative examples, patients #2914 and #2955, Fig 1E) . In ELN Adv patients (representative patients #2855 and #2817, Fig 1E) Fig 1E) . A related phenomenon, of mutually exclusive exon usage, where adjacent exons are alternately used, contributed to 185 differential events ( Fig 1D) . The retention of introns was the next most prevalent class (n=201, 15.6%, Fig 1D) in TCGA-ELN Adv patients, as seen in the representative example of the retention of intron 8 in CDK10 (increased intron-specific reads and a decrease in exon-exon reads in ELN Adv patients, Fig 1F) . Additional examples of differential 3' or 5' splice site usages are shown in Supplementary Figs 1B and 1C respectively.
To validate these findings, we analyzed an independent cohort of AML patients from the Scandinavian Clinseq study 39, 45 . Selecting the patients similarly to the TCGA cohort, we performed differential splicing analyses between Clinseq-ELN Fav (n=47) and ELN Adv (n= 75) patients ( Fig 1G) . We detected a total of 2484 alternative splicing events (FDR ≤0.05), affecting 1566 genes ( Fig 1H and Supplementary Table 3 ). As in the TCGA cohort, the majority of the events in the Clinseq data were skipped exons (n=1217, 48.9%, Fig 1H and Supplementary Fig   1A) . Mutually exclusive exon usage was the next most prevalent (n=854, 34.4%) followed by intron retention (n=232, 9.25%, Fig 1H) . Comparing both cohorts, we found differential splicing events occurring in the same direction, i.e. enriched either in ELN Adv patients in both cohorts, or in ELN Fav patients in both cohorts, in 222 genes Supplementary Table 4 ). Of these, 93 splicing events (in 78 genes) were identical in both cohorts, which we define as Class A events. A second class, Class B (244 events/173 genes in TCGA, 424 events/182 genes in Clinseq), affected the same gene and with the same directionality but represented different splicing events or occurred at different locations within the gene in the two cohorts. In 19 genes, we observed splicing occurring in opposite directions between the two cohorts.
To determine the molecular impact of this alternative splicing, we performed pathway analyses. Ingenuity Pathway Analysis of the Class A plus Class B genes revealed enrichment for a number of pathways, including those with functions related protein translation or intracellular signaling ( Fig 1J and Supplementary Table 5 ).
Orthogonal gene ontology-based analyses also supported these findings, with enrichment for pathways related to protein translation and RNA processing ( Supplementary Fig 1D) . Our data reveals recurrent and shared alternative splicing differences between AML patients with good or poor prognosis in two independent cohorts, converging on specific molecular pathways.
Prediction of the functional consequences of alternative splicing
Analogous to genetic mutations, we expected that while some splicing events would have potentially deleterious effects on subsequent protein translation, others might be silent. To identify deleterious splicing events, we developed a custom bioinformatics pipeline (described in Methods). Briefly, the chromosomal coordinates of each splicing event were used to generate nucleotide sequences for the spliced and unspliced transcripts. These were then in silico translated and the generated primary sequences were scanned to predict the protein effect (Fig 2A) .
Using this methodological framework, we predict that 26% of the Class A plus Class B events (n=87, Fig 2B) cause a complete loss of well-annotated protein domains. The majority of these events involved intron retention events that alter the reading frame ( Fig 2B) . An example of this is the retention of intron 8 of the splicing regulator HNRPH1 disrupting the RNA Recognition Motif (RRM) protein domain ( Fig 2C) and an altered transcript predicted to trigger nonsense-mediated decay. An additional 20% of events (n=67) lead to a partial loss of protein domains ( Fig 2B) .
The functional consequences of a partial loss of a domain are harder to predict a priori and likely to be protein-specific. Furthermore, of the remaining 181 events (~54%) of unknown consequence ( Fig 2B) , we cannot rule out that some may also affect protein function, through altering protein secondary structure or unannotated domains. Focusing on the events leading to a complete domain loss, pathway analysis revealed that proteins affected by aberrant splicing are still enriched for specific molecular functions, including protein translation ( Fig 2D) , which we previously observed ( Fig 1J) . Our results suggest that alternative splicing changes leading to predicted protein dysfunction in genes involved in protein translation recurrently occur in AML patients.
Analysis of the upstream drivers of alternative splicing differences
We next sought to understand the underlying reasons for the splicing differences in these risk groups. We investigated whether any of the somatic driver mutations (in the absence of splicing factor mutations) are correlated with the alternative splicing differences. We clustered patients based on the similarity of their splicing of Class A and B events and assessed the enrichment for somatic mutations within the clusters (Fig 2E) . Apart from NPM1, TP53 and CEBPA mutations, which are intrinsic to the ELN classification algorithm, no other somatic driver mutation showed any statistically significant correlation with the splicing groups ( Fig 2E) .
Amongst the alternatively spliced genes, we observed there were RNA binding proteins including factors with known roles in RNA splicing ( Fig 3A) . There was a trend for a greater number of predicted domain-altering events in these factors in ELN Adv AML patients compared to ELN Fav patients ( Fig 3B) . In addition, these factors form a tightly inter-connected network with multiple known protein-protein interactions ( Fig 3C) , suggesting that missplicing of these factors could trigger a cascade of splicing alterations in AML patients. To find evidence for this, we performed motif-scanning analyses 40 of the differentially spliced transcripts to determine if they might be targets for the misspliced splicing factors. RNA maps produced by rMAPS 40 indicated that a significant number of exons differentially retained in ELN Adv AML have a target motif for HNRNPA1 ( Fig 3D) . Our informatics pipeline prediction was that the detected alternative splicing in HNRNPA1, a multi-functional splicing regulator that is known to act as a splicing repressor 46, 47 , would produce a non-functional protein in ELN Adv patients. Consistent with this, exon inclusion in ELN Adv patients was higher within transcripts where it would normally bind and repress splicing ( Fig 3D) . Conversely, HNRNPC is a splicing factor whose function is to repress exon inclusion 48 and predicted to be nonfunctional in ELN Fav AML. Consistent with our predictions, we observed enrichment for HNRNPC motifs flanking exons that were differentially retained in ELN Fav AML patients ( Fig 3E) .
Extending motif analyses further, we found increased usage of non-canonical bases at the donor ( Fig 3F) and acceptor ( Supplementary Fig 2A) splice sites adjacent to exons differentially skipped in ELN Adv patients. Furthermore, these skipped exons also have weaker donor sites 49, 50 (Fig 3G) . To determine whether dysregulation of other RNA binding factors (in addition to the ones we have already predicted above)
might be contributing to differential splicing, we analyzed a catalogue of 114 wellcharacterized RNA binding motifs 40 . We found enrichment of motifs for PABPC1, a RNA binding protein recently proposed to have roles in RNA splicing 51 , and for RBM46 adjacent to exons that were retained in ELN Adv patients (Supplementary Figs 2B-C). Similarly, introns that were preferentially retained in ELN Adv were enriched for SRSF3 binding at the 3' end ( Supplementary Fig 2D) . These RNA binding factors are also known to have protein-protein interactions with other splicing proteins predicted by our analyses to be affected by differential splicing ( Supplementary Fig   2E) . Our results suggest that missplicing of splicing factors, together with specific biophysical properties of cis-factors, contribute to the alternative splicing differences we have observed in AML patients.
Induction of an integrated stress response in ELN Adv AML patients
Our analyses had indicated that genes related to protein translation were differentially spliced ( Fig 1J) , with predicted functional impairment ( Fig 2D) in ELN Adv AML patients. A cellular consequence of impaired protein translation would be the induction of the Integrated Stress Response (ISR) within cells 52 . To find evidence in support of this, we performed differential gene expression analyses between ELN Fav and ELN Adv patients ( Fig 4A) . 2219 genes were differentially expressed in the TCGA cohort at FDR <0.05 (Fig 4B, Supplementary Table 6 ), and 1710 genes in Clinseq (Fig 4B, Supplementary Table 6 ). GSEA analyses of the differentially expressed genes clearly indicate a strong up-regulation of ISR genes 53 in ELN Adv AML patients in both cohorts ( Fig 4C) . Additionally, individual patient analyses revealed a proportional trend between the strength of the induction of ISR gene expression and the extent of missplicing of protein translation genes within the same patient ( Fig 4D) . ELN Adv patients, who had higher levels of expression of ISR target genes, tended to have higher levels of missplicing of protein translation genes ( Fig 4D) .
It has recently been shown that metabolic stresses including amino acid deprivation that decrease protein synthesis trigger a pro-inflammatory response 54 .
Pathway analyses of the 602 genes that were commonly differentially expressed in the same direction in both cohorts (i.e. either up-regulated in ELN Adv both cohorts, or down-regulated in both cohorts, Supplemental Table 5 ) revealed an enrichment for a number of inflammation-related pathways ( Fig 4E) . We find an up-regulation of these stress-induced inflammatory genes in ELN Adv AML patients in whom protein translation is impacted due to splicing ( Fig 4F) . Network analyses further confirm strong interconnections between the misspliced translation-related genes and the differentially expressed pro-inflammation genes in ELN Adv AML ( Fig 4G) . Our data supports a scenario where missplicing of protein translation genes trigger a proinflammatory stress response in ELN Adv patients.
Determining the prognostic relevance of alternative splicing events
Given these findings, we examined whether alternative splicing could serve as a prognostic marker for adverse outcomes in AML. While gene expression and epigenetic studies have been previously linked to AML outcome [55] [56] [57] [58] , these analyses would have missed the impact of alternative splicing. Utilizing machine-learning techniques (schematized in Fig 5A; see Supplementary methods for more details), we identified four genes (MYO9B, GAS5, GIGYF2, RPS9, Fig 5B) whose differential alternative splicing could stratify AML patients with good and poor prognosis. The differential splicing of these four genes ("splicing signature") performs comparably to the ELN in both cohorts ( Fig 5C) , with similar Harrell's C-statistic 43, 59 ( Supplementary Fig 3A) where a C-statistic of 50% is equivalent to a random assignment and 100% represents a correct ranking of the survival times of all patients.
More accurate stratification and improved prognosis would especially benefit To independently validate the prognostic significance of the splicing signature, we also analyzed data from the BEAT-AML cohort 7 . Selecting patients as for the TCGA and Clinseq cohorts, we performed RNA splicing analyses on the transcriptomic data and calculated the splicing risk score (see Supplementary methods for details). Applying the splicing signature significantly improved ELN 2017 based prognostic classification (p = 0.0018 vs p= 0.035, Fig 5E) , converting the three-group risk classification into one with two groups with significantly different overall survival.
Discussion
Recurrent somatic mutations in RNA splicing factors have been reported in several hematological malignancies 60 . Analyzing AML transcriptomes, we have discovered recurrent alternative RNA splicing differences between ELN Fav and ELN Adv patients even in the absence of splicing factor mutations. Many of these alternatively spliced events are predicted to alter protein function, including members of the spliceosomal complex and protein translation genes. Integration with gene expression revealed that ELN Adv patients had an induction of the ISR and a proinflammatory transcriptional program that was proportional to the degree of missplicing of protein translation genes. Furthermore, using machine learning, we identified four alternatively spliced genes that could be used to refine current mutation and transcriptome based prognostic classification of AML patients.
The origin of the missplicing that we have detected in AML patients remains unknown. It is possible that aberrant transcriptional programs initiated by oncogenic driver mutations might dysregulate splicing networks through the mis-expression of splicing co-factors. The splicing factors are also subject to a number of regulatory post-translational modifications. Phosphorylation of splicing factors by kinases of the SRPK and CLK families control their enzymatic activity and subcellular localization 61 and AML cells are sensitive to pharmacological inhibition of these kinases 62 . Many RNA binding proteins are also methylated by the PRMT family of protein arginine methyltransferases and PRMT inhibition kills leukemic cells 63 . Furthermore, splicing alterations due to epigenetic or chromatin changes due to somatic mutations 44, 64 or possibly as a consequence of aging 65 have also been recently reported. It is possible that some or all of these mechanisms could contribute to the splicing alterations we have detected in AML. A cascade of missplicing would then be predicted to arise because of the highly-interconnected regulatory networks involving a number of splicing factors and RNA binding proteins 32, 46 .
Decreased protein translation induces the ISR, a conserved pathway which serves promotes cell survival by modulating cellular homeostasis during cellular stress 52 . Protein translational stress leads to the efficient translation of the ISR effector ATF4 and upregulation of its target genes 52 . Increased ISR and ATF4 activity have been recently shown to be marker of leukaemic stem cells in AML patients 53 vulnerability of leukemic cells 65, [68] [69] [70] [71] , the narrow therapeutic window for these drugs due to toxicity poses a potential challenge to using them clinically. Our data suggests that targeting integrated stress response or inflammation-promoting pathways that might be stimulated in leukemic cells as a consequence of missplicing could be an alternative approach.
While cytogenetic and mutational information have become the clinical standard for prognosis in AML, there is still significant heterogeneity that remains unresolved. Assessing additional molecular parameters, including gene expression 56, 58 and DNA methylation 55 
Conflict of Interest Disclosures,
The authors declare no competing interests. 
Figure Legends
Beat-AML cohort
